Global Companion Diagnostics for Oncology Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Companion Diagnostics for Oncology market size was valued at US$ 4011.8 million in 2023. With growing demand in downstream market, the Companion Diagnostics for Oncology is forecast to a readjusted size of US$ 8436.7 million by 2030 with a CAGR of 11.2% during review period.
The research report highlights the growth potential of the global Companion Diagnostics for Oncology market. Companion Diagnostics for Oncology are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Companion Diagnostics for Oncology. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Companion Diagnostics for Oncology market.
Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Companion Diagnostics for Oncology market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Companion Diagnostics for Oncology market. It may include historical data, market segmentation by Type (e.g., Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Companion Diagnostics for Oncology market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Companion Diagnostics for Oncology market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Companion Diagnostics for Oncology industry. This include advancements in Companion Diagnostics for Oncology technology, Companion Diagnostics for Oncology new entrants, Companion Diagnostics for Oncology new investment, and other innovations that are shaping the future of Companion Diagnostics for Oncology.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Companion Diagnostics for Oncology market. It includes factors influencing customer ' purchasing decisions, preferences for Companion Diagnostics for Oncology product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Companion Diagnostics for Oncology market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Companion Diagnostics for Oncology market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Companion Diagnostics for Oncology market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Companion Diagnostics for Oncology industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Companion Diagnostics for Oncology market.
Market Segmentation:
Companion Diagnostics for Oncology market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Companion Diagnostics for Oncology market size was valued at US$ 4011.8 million in 2023. With growing demand in downstream market, the Companion Diagnostics for Oncology is forecast to a readjusted size of US$ 8436.7 million by 2030 with a CAGR of 11.2% during review period.
The research report highlights the growth potential of the global Companion Diagnostics for Oncology market. Companion Diagnostics for Oncology are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Companion Diagnostics for Oncology. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Companion Diagnostics for Oncology market.
Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Companion Diagnostics for Oncology market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Companion Diagnostics for Oncology market. It may include historical data, market segmentation by Type (e.g., Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Companion Diagnostics for Oncology market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Companion Diagnostics for Oncology market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Companion Diagnostics for Oncology industry. This include advancements in Companion Diagnostics for Oncology technology, Companion Diagnostics for Oncology new entrants, Companion Diagnostics for Oncology new investment, and other innovations that are shaping the future of Companion Diagnostics for Oncology.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Companion Diagnostics for Oncology market. It includes factors influencing customer ' purchasing decisions, preferences for Companion Diagnostics for Oncology product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Companion Diagnostics for Oncology market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Companion Diagnostics for Oncology market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Companion Diagnostics for Oncology market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Companion Diagnostics for Oncology industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Companion Diagnostics for Oncology market.
Market Segmentation:
Companion Diagnostics for Oncology market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Laboratories
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Agilent Technologies
- Illumina
- Roche
- BioMйrieux
- Foundation Medicine
- ArcherDX
- Qiagen
- Thermo Fisher Scientific
- Amoy Diagnostics
- Abbott
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Companion Diagnostics for Oncology Market Size 2019-2030
2.1.2 Companion Diagnostics for Oncology Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Companion Diagnostics for Oncology Segment by Type
2.2.1 Polymerase Chain Reaction (PCR)
2.2.2 Next-Generation Sequencing (NGS)
2.3 Companion Diagnostics for Oncology Market Size by Type
2.3.1 Companion Diagnostics for Oncology Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
2.4 Companion Diagnostics for Oncology Segment by Application
2.4.1 Pharmaceutical and Biopharmaceutical Companies
2.4.2 Contract Research Organizations
2.4.3 Laboratories
2.4.4 Others
2.5 Companion Diagnostics for Oncology Market Size by Application
2.5.1 Companion Diagnostics for Oncology Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
3 COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE BY PLAYER
3.1 Companion Diagnostics for Oncology Market Size Market Share by Players
3.1.1 Global Companion Diagnostics for Oncology Revenue by Players (2019-2024)
3.1.2 Global Companion Diagnostics for Oncology Revenue Market Share by Players (2019-2024)
3.2 Global Companion Diagnostics for Oncology Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 COMPANION DIAGNOSTICS FOR ONCOLOGY BY REGIONS
4.1 Companion Diagnostics for Oncology Market Size by Regions (2019-2024)
4.2 Americas Companion Diagnostics for Oncology Market Size Growth (2019-2024)
4.3 APAC Companion Diagnostics for Oncology Market Size Growth (2019-2024)
4.4 Europe Companion Diagnostics for Oncology Market Size Growth (2019-2024)
4.5 Middle East & Africa Companion Diagnostics for Oncology Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Companion Diagnostics for Oncology Market Size by Country (2019-2024)
5.2 Americas Companion Diagnostics for Oncology Market Size by Type (2019-2024)
5.3 Americas Companion Diagnostics for Oncology Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Companion Diagnostics for Oncology Market Size by Region (2019-2024)
6.2 APAC Companion Diagnostics for Oncology Market Size by Type (2019-2024)
6.3 APAC Companion Diagnostics for Oncology Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Companion Diagnostics for Oncology by Country (2019-2024)
7.2 Europe Companion Diagnostics for Oncology Market Size by Type (2019-2024)
7.3 Europe Companion Diagnostics for Oncology Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Companion Diagnostics for Oncology by Region (2019-2024)
8.2 Middle East & Africa Companion Diagnostics for Oncology Market Size by Type (2019-2024)
8.3 Middle East & Africa Companion Diagnostics for Oncology Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET FORECAST
10.1 Global Companion Diagnostics for Oncology Forecast by Regions (2025-2030)
10.1.1 Global Companion Diagnostics for Oncology Forecast by Regions (2025-2030)
10.1.2 Americas Companion Diagnostics for Oncology Forecast
10.1.3 APAC Companion Diagnostics for Oncology Forecast
10.1.4 Europe Companion Diagnostics for Oncology Forecast
10.1.5 Middle East & Africa Companion Diagnostics for Oncology Forecast
10.2 Americas Companion Diagnostics for Oncology Forecast by Country (2025-2030)
10.2.1 United States Companion Diagnostics for Oncology Market Forecast
10.2.2 Canada Companion Diagnostics for Oncology Market Forecast
10.2.3 Mexico Companion Diagnostics for Oncology Market Forecast
10.2.4 Brazil Companion Diagnostics for Oncology Market Forecast
10.3 APAC Companion Diagnostics for Oncology Forecast by Region (2025-2030)
10.3.1 China Companion Diagnostics for Oncology Market Forecast
10.3.2 Japan Companion Diagnostics for Oncology Market Forecast
10.3.3 Korea Companion Diagnostics for Oncology Market Forecast
10.3.4 Southeast Asia Companion Diagnostics for Oncology Market Forecast
10.3.5 India Companion Diagnostics for Oncology Market Forecast
10.3.6 Australia Companion Diagnostics for Oncology Market Forecast
10.4 Europe Companion Diagnostics for Oncology Forecast by Country (2025-2030)
10.4.1 Germany Companion Diagnostics for Oncology Market Forecast
10.4.2 France Companion Diagnostics for Oncology Market Forecast
10.4.3 UK Companion Diagnostics for Oncology Market Forecast
10.4.4 Italy Companion Diagnostics for Oncology Market Forecast
10.4.5 Russia Companion Diagnostics for Oncology Market Forecast
10.5 Middle East & Africa Companion Diagnostics for Oncology Forecast by Region (2025-2030)
10.5.1 Egypt Companion Diagnostics for Oncology Market Forecast
10.5.2 South Africa Companion Diagnostics for Oncology Market Forecast
10.5.3 Israel Companion Diagnostics for Oncology Market Forecast
10.5.4 Turkey Companion Diagnostics for Oncology Market Forecast
10.5.5 GCC Countries Companion Diagnostics for Oncology Market Forecast
10.6 Global Companion Diagnostics for Oncology Forecast by Type (2025-2030)
10.7 Global Companion Diagnostics for Oncology Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Information
11.1.2 Agilent Technologies Companion Diagnostics for Oncology Product Offered
11.1.3 Agilent Technologies Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Agilent Technologies Main Business Overview
11.1.5 Agilent Technologies Latest Developments
11.2 Illumina
11.2.1 Illumina Company Information
11.2.2 Illumina Companion Diagnostics for Oncology Product Offered
11.2.3 Illumina Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Illumina Main Business Overview
11.2.5 Illumina Latest Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Companion Diagnostics for Oncology Product Offered
11.3.3 Roche Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Roche Main Business Overview
11.3.5 Roche Latest Developments
11.4 BioMйrieux
11.4.1 BioMйrieux Company Information
11.4.2 BioMйrieux Companion Diagnostics for Oncology Product Offered
11.4.3 BioMйrieux Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 BioMйrieux Main Business Overview
11.4.5 BioMйrieux Latest Developments
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Information
11.5.2 Foundation Medicine Companion Diagnostics for Oncology Product Offered
11.5.3 Foundation Medicine Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Foundation Medicine Main Business Overview
11.5.5 Foundation Medicine Latest Developments
11.6 ArcherDX
11.6.1 ArcherDX Company Information
11.6.2 ArcherDX Companion Diagnostics for Oncology Product Offered
11.6.3 ArcherDX Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 ArcherDX Main Business Overview
11.6.5 ArcherDX Latest Developments
11.7 Qiagen
11.7.1 Qiagen Company Information
11.7.2 Qiagen Companion Diagnostics for Oncology Product Offered
11.7.3 Qiagen Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Qiagen Main Business Overview
11.7.5 Qiagen Latest Developments
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Information
11.8.2 Thermo Fisher Scientific Companion Diagnostics for Oncology Product Offered
11.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Thermo Fisher Scientific Main Business Overview
11.8.5 Thermo Fisher Scientific Latest Developments
11.9 Amoy Diagnostics
11.9.1 Amoy Diagnostics Company Information
11.9.2 Amoy Diagnostics Companion Diagnostics for Oncology Product Offered
11.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Amoy Diagnostics Main Business Overview
11.9.5 Amoy Diagnostics Latest Developments
11.10 Abbott
11.10.1 Abbott Company Information
11.10.2 Abbott Companion Diagnostics for Oncology Product Offered
11.10.3 Abbott Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Abbott Main Business Overview
11.10.5 Abbott Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Companion Diagnostics for Oncology Market Size 2019-2030
2.1.2 Companion Diagnostics for Oncology Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Companion Diagnostics for Oncology Segment by Type
2.2.1 Polymerase Chain Reaction (PCR)
2.2.2 Next-Generation Sequencing (NGS)
2.3 Companion Diagnostics for Oncology Market Size by Type
2.3.1 Companion Diagnostics for Oncology Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
2.4 Companion Diagnostics for Oncology Segment by Application
2.4.1 Pharmaceutical and Biopharmaceutical Companies
2.4.2 Contract Research Organizations
2.4.3 Laboratories
2.4.4 Others
2.5 Companion Diagnostics for Oncology Market Size by Application
2.5.1 Companion Diagnostics for Oncology Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
3 COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE BY PLAYER
3.1 Companion Diagnostics for Oncology Market Size Market Share by Players
3.1.1 Global Companion Diagnostics for Oncology Revenue by Players (2019-2024)
3.1.2 Global Companion Diagnostics for Oncology Revenue Market Share by Players (2019-2024)
3.2 Global Companion Diagnostics for Oncology Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 COMPANION DIAGNOSTICS FOR ONCOLOGY BY REGIONS
4.1 Companion Diagnostics for Oncology Market Size by Regions (2019-2024)
4.2 Americas Companion Diagnostics for Oncology Market Size Growth (2019-2024)
4.3 APAC Companion Diagnostics for Oncology Market Size Growth (2019-2024)
4.4 Europe Companion Diagnostics for Oncology Market Size Growth (2019-2024)
4.5 Middle East & Africa Companion Diagnostics for Oncology Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Companion Diagnostics for Oncology Market Size by Country (2019-2024)
5.2 Americas Companion Diagnostics for Oncology Market Size by Type (2019-2024)
5.3 Americas Companion Diagnostics for Oncology Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Companion Diagnostics for Oncology Market Size by Region (2019-2024)
6.2 APAC Companion Diagnostics for Oncology Market Size by Type (2019-2024)
6.3 APAC Companion Diagnostics for Oncology Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Companion Diagnostics for Oncology by Country (2019-2024)
7.2 Europe Companion Diagnostics for Oncology Market Size by Type (2019-2024)
7.3 Europe Companion Diagnostics for Oncology Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Companion Diagnostics for Oncology by Region (2019-2024)
8.2 Middle East & Africa Companion Diagnostics for Oncology Market Size by Type (2019-2024)
8.3 Middle East & Africa Companion Diagnostics for Oncology Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET FORECAST
10.1 Global Companion Diagnostics for Oncology Forecast by Regions (2025-2030)
10.1.1 Global Companion Diagnostics for Oncology Forecast by Regions (2025-2030)
10.1.2 Americas Companion Diagnostics for Oncology Forecast
10.1.3 APAC Companion Diagnostics for Oncology Forecast
10.1.4 Europe Companion Diagnostics for Oncology Forecast
10.1.5 Middle East & Africa Companion Diagnostics for Oncology Forecast
10.2 Americas Companion Diagnostics for Oncology Forecast by Country (2025-2030)
10.2.1 United States Companion Diagnostics for Oncology Market Forecast
10.2.2 Canada Companion Diagnostics for Oncology Market Forecast
10.2.3 Mexico Companion Diagnostics for Oncology Market Forecast
10.2.4 Brazil Companion Diagnostics for Oncology Market Forecast
10.3 APAC Companion Diagnostics for Oncology Forecast by Region (2025-2030)
10.3.1 China Companion Diagnostics for Oncology Market Forecast
10.3.2 Japan Companion Diagnostics for Oncology Market Forecast
10.3.3 Korea Companion Diagnostics for Oncology Market Forecast
10.3.4 Southeast Asia Companion Diagnostics for Oncology Market Forecast
10.3.5 India Companion Diagnostics for Oncology Market Forecast
10.3.6 Australia Companion Diagnostics for Oncology Market Forecast
10.4 Europe Companion Diagnostics for Oncology Forecast by Country (2025-2030)
10.4.1 Germany Companion Diagnostics for Oncology Market Forecast
10.4.2 France Companion Diagnostics for Oncology Market Forecast
10.4.3 UK Companion Diagnostics for Oncology Market Forecast
10.4.4 Italy Companion Diagnostics for Oncology Market Forecast
10.4.5 Russia Companion Diagnostics for Oncology Market Forecast
10.5 Middle East & Africa Companion Diagnostics for Oncology Forecast by Region (2025-2030)
10.5.1 Egypt Companion Diagnostics for Oncology Market Forecast
10.5.2 South Africa Companion Diagnostics for Oncology Market Forecast
10.5.3 Israel Companion Diagnostics for Oncology Market Forecast
10.5.4 Turkey Companion Diagnostics for Oncology Market Forecast
10.5.5 GCC Countries Companion Diagnostics for Oncology Market Forecast
10.6 Global Companion Diagnostics for Oncology Forecast by Type (2025-2030)
10.7 Global Companion Diagnostics for Oncology Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Information
11.1.2 Agilent Technologies Companion Diagnostics for Oncology Product Offered
11.1.3 Agilent Technologies Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Agilent Technologies Main Business Overview
11.1.5 Agilent Technologies Latest Developments
11.2 Illumina
11.2.1 Illumina Company Information
11.2.2 Illumina Companion Diagnostics for Oncology Product Offered
11.2.3 Illumina Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Illumina Main Business Overview
11.2.5 Illumina Latest Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Companion Diagnostics for Oncology Product Offered
11.3.3 Roche Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Roche Main Business Overview
11.3.5 Roche Latest Developments
11.4 BioMйrieux
11.4.1 BioMйrieux Company Information
11.4.2 BioMйrieux Companion Diagnostics for Oncology Product Offered
11.4.3 BioMйrieux Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 BioMйrieux Main Business Overview
11.4.5 BioMйrieux Latest Developments
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Information
11.5.2 Foundation Medicine Companion Diagnostics for Oncology Product Offered
11.5.3 Foundation Medicine Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Foundation Medicine Main Business Overview
11.5.5 Foundation Medicine Latest Developments
11.6 ArcherDX
11.6.1 ArcherDX Company Information
11.6.2 ArcherDX Companion Diagnostics for Oncology Product Offered
11.6.3 ArcherDX Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 ArcherDX Main Business Overview
11.6.5 ArcherDX Latest Developments
11.7 Qiagen
11.7.1 Qiagen Company Information
11.7.2 Qiagen Companion Diagnostics for Oncology Product Offered
11.7.3 Qiagen Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Qiagen Main Business Overview
11.7.5 Qiagen Latest Developments
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Information
11.8.2 Thermo Fisher Scientific Companion Diagnostics for Oncology Product Offered
11.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Thermo Fisher Scientific Main Business Overview
11.8.5 Thermo Fisher Scientific Latest Developments
11.9 Amoy Diagnostics
11.9.1 Amoy Diagnostics Company Information
11.9.2 Amoy Diagnostics Companion Diagnostics for Oncology Product Offered
11.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Amoy Diagnostics Main Business Overview
11.9.5 Amoy Diagnostics Latest Developments
11.10 Abbott
11.10.1 Abbott Company Information
11.10.2 Abbott Companion Diagnostics for Oncology Product Offered
11.10.3 Abbott Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Abbott Main Business Overview
11.10.5 Abbott Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Companion Diagnostics for Oncology Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Polymerase Chain Reaction (PCR)
Table 3. Major Players of Next-Generation Sequencing (NGS)
Table 4. Companion Diagnostics for Oncology Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 7. Companion Diagnostics for Oncology Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 10. Global Companion Diagnostics for Oncology Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Companion Diagnostics for Oncology Revenue Market Share by Player (2019-2024)
Table 12. Companion Diagnostics for Oncology Key Players Head office and Products Offered
Table 13. Companion Diagnostics for Oncology Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Companion Diagnostics for Oncology Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Companion Diagnostics for Oncology Market Size Market Share by Regions (2019-2024)
Table 18. Global Companion Diagnostics for Oncology Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Companion Diagnostics for Oncology Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Companion Diagnostics for Oncology Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Companion Diagnostics for Oncology Market Size Market Share by Country (2019-2024)
Table 22. Americas Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 24. Americas Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 26. APAC Companion Diagnostics for Oncology Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Companion Diagnostics for Oncology Market Size Market Share by Region (2019-2024)
Table 28. APAC Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 30. APAC Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 32. Europe Companion Diagnostics for Oncology Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Companion Diagnostics for Oncology Market Size Market Share by Country (2019-2024)
Table 34. Europe Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 36. Europe Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Companion Diagnostics for Oncology Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Companion Diagnostics for Oncology
Table 45. Key Market Challenges & Risks of Companion Diagnostics for Oncology
Table 46. Key Industry Trends of Companion Diagnostics for Oncology
Table 47. Global Companion Diagnostics for Oncology Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Companion Diagnostics for Oncology Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Companion Diagnostics for Oncology Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Companion Diagnostics for Oncology Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. Agilent Technologies Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 52. Agilent Technologies Companion Diagnostics for Oncology Product Offered
Table 53. Agilent Technologies Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Agilent Technologies Main Business
Table 55. Agilent Technologies Latest Developments
Table 56. Illumina Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 57. Illumina Companion Diagnostics for Oncology Product Offered
Table 58. Illumina Main Business
Table 59. Illumina Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Illumina Latest Developments
Table 61. Roche Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 62. Roche Companion Diagnostics for Oncology Product Offered
Table 63. Roche Main Business
Table 64. Roche Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. Roche Latest Developments
Table 66. BioMйrieux Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 67. BioMйrieux Companion Diagnostics for Oncology Product Offered
Table 68. BioMйrieux Main Business
Table 69. BioMйrieux Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. BioMйrieux Latest Developments
Table 71. Foundation Medicine Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 72. Foundation Medicine Companion Diagnostics for Oncology Product Offered
Table 73. Foundation Medicine Main Business
Table 74. Foundation Medicine Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Foundation Medicine Latest Developments
Table 76. ArcherDX Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 77. ArcherDX Companion Diagnostics for Oncology Product Offered
Table 78. ArcherDX Main Business
Table 79. ArcherDX Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. ArcherDX Latest Developments
Table 81. Qiagen Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 82. Qiagen Companion Diagnostics for Oncology Product Offered
Table 83. Qiagen Main Business
Table 84. Qiagen Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. Qiagen Latest Developments
Table 86. Thermo Fisher Scientific Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 87. Thermo Fisher Scientific Companion Diagnostics for Oncology Product Offered
Table 88. Thermo Fisher Scientific Main Business
Table 89. Thermo Fisher Scientific Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. Thermo Fisher Scientific Latest Developments
Table 91. Amoy Diagnostics Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 92. Amoy Diagnostics Companion Diagnostics for Oncology Product Offered
Table 93. Amoy Diagnostics Main Business
Table 94. Amoy Diagnostics Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Amoy Diagnostics Latest Developments
Table 96. Abbott Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 97. Abbott Companion Diagnostics for Oncology Product Offered
Table 98. Abbott Main Business
Table 99. Abbott Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. Abbott Latest Developments
Table 1. Companion Diagnostics for Oncology Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Polymerase Chain Reaction (PCR)
Table 3. Major Players of Next-Generation Sequencing (NGS)
Table 4. Companion Diagnostics for Oncology Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 7. Companion Diagnostics for Oncology Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 10. Global Companion Diagnostics for Oncology Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Companion Diagnostics for Oncology Revenue Market Share by Player (2019-2024)
Table 12. Companion Diagnostics for Oncology Key Players Head office and Products Offered
Table 13. Companion Diagnostics for Oncology Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Companion Diagnostics for Oncology Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Companion Diagnostics for Oncology Market Size Market Share by Regions (2019-2024)
Table 18. Global Companion Diagnostics for Oncology Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Companion Diagnostics for Oncology Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Companion Diagnostics for Oncology Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Companion Diagnostics for Oncology Market Size Market Share by Country (2019-2024)
Table 22. Americas Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 24. Americas Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 26. APAC Companion Diagnostics for Oncology Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Companion Diagnostics for Oncology Market Size Market Share by Region (2019-2024)
Table 28. APAC Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 30. APAC Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 32. Europe Companion Diagnostics for Oncology Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Companion Diagnostics for Oncology Market Size Market Share by Country (2019-2024)
Table 34. Europe Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 36. Europe Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Companion Diagnostics for Oncology Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Companion Diagnostics for Oncology Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Companion Diagnostics for Oncology Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Companion Diagnostics for Oncology
Table 45. Key Market Challenges & Risks of Companion Diagnostics for Oncology
Table 46. Key Industry Trends of Companion Diagnostics for Oncology
Table 47. Global Companion Diagnostics for Oncology Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Companion Diagnostics for Oncology Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Companion Diagnostics for Oncology Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Companion Diagnostics for Oncology Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. Agilent Technologies Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 52. Agilent Technologies Companion Diagnostics for Oncology Product Offered
Table 53. Agilent Technologies Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Agilent Technologies Main Business
Table 55. Agilent Technologies Latest Developments
Table 56. Illumina Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 57. Illumina Companion Diagnostics for Oncology Product Offered
Table 58. Illumina Main Business
Table 59. Illumina Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Illumina Latest Developments
Table 61. Roche Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 62. Roche Companion Diagnostics for Oncology Product Offered
Table 63. Roche Main Business
Table 64. Roche Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. Roche Latest Developments
Table 66. BioMйrieux Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 67. BioMйrieux Companion Diagnostics for Oncology Product Offered
Table 68. BioMйrieux Main Business
Table 69. BioMйrieux Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. BioMйrieux Latest Developments
Table 71. Foundation Medicine Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 72. Foundation Medicine Companion Diagnostics for Oncology Product Offered
Table 73. Foundation Medicine Main Business
Table 74. Foundation Medicine Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Foundation Medicine Latest Developments
Table 76. ArcherDX Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 77. ArcherDX Companion Diagnostics for Oncology Product Offered
Table 78. ArcherDX Main Business
Table 79. ArcherDX Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. ArcherDX Latest Developments
Table 81. Qiagen Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 82. Qiagen Companion Diagnostics for Oncology Product Offered
Table 83. Qiagen Main Business
Table 84. Qiagen Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. Qiagen Latest Developments
Table 86. Thermo Fisher Scientific Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 87. Thermo Fisher Scientific Companion Diagnostics for Oncology Product Offered
Table 88. Thermo Fisher Scientific Main Business
Table 89. Thermo Fisher Scientific Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. Thermo Fisher Scientific Latest Developments
Table 91. Amoy Diagnostics Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 92. Amoy Diagnostics Companion Diagnostics for Oncology Product Offered
Table 93. Amoy Diagnostics Main Business
Table 94. Amoy Diagnostics Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Amoy Diagnostics Latest Developments
Table 96. Abbott Details, Company Type, Companion Diagnostics for Oncology Area Served and Its Competitors
Table 97. Abbott Companion Diagnostics for Oncology Product Offered
Table 98. Abbott Main Business
Table 99. Abbott Companion Diagnostics for Oncology Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. Abbott Latest Developments
LIST OF FIGURES
Figure 1. Companion Diagnostics for Oncology Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Companion Diagnostics for Oncology Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Companion Diagnostics for Oncology Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Companion Diagnostics for Oncology Sales Market Share by Country/Region (2023)
Figure 8. Companion Diagnostics for Oncology Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Companion Diagnostics for Oncology Market Size Market Share by Type in 2023
Figure 10. Companion Diagnostics for Oncology in Pharmaceutical and Biopharmaceutical Companies
Figure 11. Global Companion Diagnostics for Oncology Market: Pharmaceutical and Biopharmaceutical Companies (2019-2024) & ($ Millions)
Figure 12. Companion Diagnostics for Oncology in Contract Research Organizations
Figure 13. Global Companion Diagnostics for Oncology Market: Contract Research Organizations (2019-2024) & ($ Millions)
Figure 14. Companion Diagnostics for Oncology in Laboratories
Figure 15. Global Companion Diagnostics for Oncology Market: Laboratories (2019-2024) & ($ Millions)
Figure 16. Companion Diagnostics for Oncology in Others
Figure 17. Global Companion Diagnostics for Oncology Market: Others (2019-2024) & ($ Millions)
Figure 18. Global Companion Diagnostics for Oncology Market Size Market Share by Application in 2023
Figure 19. Global Companion Diagnostics for Oncology Revenue Market Share by Player in 2023
Figure 20. Global Companion Diagnostics for Oncology Market Size Market Share by Regions (2019-2024)
Figure 21. Americas Companion Diagnostics for Oncology Market Size 2019-2024 ($ Millions)
Figure 22. APAC Companion Diagnostics for Oncology Market Size 2019-2024 ($ Millions)
Figure 23. Europe Companion Diagnostics for Oncology Market Size 2019-2024 ($ Millions)
Figure 24. Middle East & Africa Companion Diagnostics for Oncology Market Size 2019-2024 ($ Millions)
Figure 25. Americas Companion Diagnostics for Oncology Value Market Share by Country in 2023
Figure 26. United States Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 27. Canada Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 28. Mexico Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 29. Brazil Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 30. APAC Companion Diagnostics for Oncology Market Size Market Share by Region in 2023
Figure 31. APAC Companion Diagnostics for Oncology Market Size Market Share by Type in 2023
Figure 32. APAC Companion Diagnostics for Oncology Market Size Market Share by Application in 2023
Figure 33. China Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 34. Japan Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 35. Korea Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 36. Southeast Asia Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 37. India Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 38. Australia Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 39. Europe Companion Diagnostics for Oncology Market Size Market Share by Country in 2023
Figure 40. Europe Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Figure 41. Europe Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Figure 42. Germany Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 43. France Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 44. UK Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 45. Italy Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 46. Russia Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 47. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 51. South Africa Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 52. Israel Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 53. Turkey Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 54. GCC Country Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 55. Americas Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 56. APAC Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 57. Europe Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 58. Middle East & Africa Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 59. United States Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 60. Canada Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 61. Mexico Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 62. Brazil Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 63. China Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 64. Japan Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 65. Korea Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 66. Southeast Asia Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 67. India Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 68. Australia Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 69. Germany Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 70. France Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 71. UK Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 72. Italy Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 73. Russia Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 74. Spain Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 75. Egypt Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 76. South Africa Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 77. Israel Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 78. Turkey Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 79. GCC Countries Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 80. Global Companion Diagnostics for Oncology Market Size Market Share Forecast by Type (2025-2030)
Figure 81. Global Companion Diagnostics for Oncology Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Companion Diagnostics for Oncology Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Companion Diagnostics for Oncology Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Companion Diagnostics for Oncology Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Companion Diagnostics for Oncology Sales Market Share by Country/Region (2023)
Figure 8. Companion Diagnostics for Oncology Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Companion Diagnostics for Oncology Market Size Market Share by Type in 2023
Figure 10. Companion Diagnostics for Oncology in Pharmaceutical and Biopharmaceutical Companies
Figure 11. Global Companion Diagnostics for Oncology Market: Pharmaceutical and Biopharmaceutical Companies (2019-2024) & ($ Millions)
Figure 12. Companion Diagnostics for Oncology in Contract Research Organizations
Figure 13. Global Companion Diagnostics for Oncology Market: Contract Research Organizations (2019-2024) & ($ Millions)
Figure 14. Companion Diagnostics for Oncology in Laboratories
Figure 15. Global Companion Diagnostics for Oncology Market: Laboratories (2019-2024) & ($ Millions)
Figure 16. Companion Diagnostics for Oncology in Others
Figure 17. Global Companion Diagnostics for Oncology Market: Others (2019-2024) & ($ Millions)
Figure 18. Global Companion Diagnostics for Oncology Market Size Market Share by Application in 2023
Figure 19. Global Companion Diagnostics for Oncology Revenue Market Share by Player in 2023
Figure 20. Global Companion Diagnostics for Oncology Market Size Market Share by Regions (2019-2024)
Figure 21. Americas Companion Diagnostics for Oncology Market Size 2019-2024 ($ Millions)
Figure 22. APAC Companion Diagnostics for Oncology Market Size 2019-2024 ($ Millions)
Figure 23. Europe Companion Diagnostics for Oncology Market Size 2019-2024 ($ Millions)
Figure 24. Middle East & Africa Companion Diagnostics for Oncology Market Size 2019-2024 ($ Millions)
Figure 25. Americas Companion Diagnostics for Oncology Value Market Share by Country in 2023
Figure 26. United States Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 27. Canada Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 28. Mexico Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 29. Brazil Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 30. APAC Companion Diagnostics for Oncology Market Size Market Share by Region in 2023
Figure 31. APAC Companion Diagnostics for Oncology Market Size Market Share by Type in 2023
Figure 32. APAC Companion Diagnostics for Oncology Market Size Market Share by Application in 2023
Figure 33. China Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 34. Japan Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 35. Korea Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 36. Southeast Asia Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 37. India Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 38. Australia Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 39. Europe Companion Diagnostics for Oncology Market Size Market Share by Country in 2023
Figure 40. Europe Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Figure 41. Europe Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Figure 42. Germany Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 43. France Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 44. UK Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 45. Italy Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 46. Russia Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 47. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Companion Diagnostics for Oncology Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 51. South Africa Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 52. Israel Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 53. Turkey Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 54. GCC Country Companion Diagnostics for Oncology Market Size Growth 2019-2024 ($ Millions)
Figure 55. Americas Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 56. APAC Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 57. Europe Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 58. Middle East & Africa Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 59. United States Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 60. Canada Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 61. Mexico Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 62. Brazil Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 63. China Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 64. Japan Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 65. Korea Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 66. Southeast Asia Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 67. India Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 68. Australia Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 69. Germany Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 70. France Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 71. UK Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 72. Italy Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 73. Russia Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 74. Spain Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 75. Egypt Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 76. South Africa Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 77. Israel Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 78. Turkey Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 79. GCC Countries Companion Diagnostics for Oncology Market Size 2025-2030 ($ Millions)
Figure 80. Global Companion Diagnostics for Oncology Market Size Market Share Forecast by Type (2025-2030)
Figure 81. Global Companion Diagnostics for Oncology Market Size Market Share Forecast by Application (2025-2030)
